INMB241220C5000
- 0.30
- -0.05-14.29%
INmune Bio Newsroom
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
Inmune Bio Emerges as Biotech Innovator in 2023
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
Inmune Bio's Promising Pipeline and Financial Stability Justify Buy Rating
INmune Bio | 8-K: INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
Earnings Call: INmune Bio Q3 2024 Results Show Progress in Clinical Trials
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript Summary
INmune Bio GAAP EPS of -$0.60 Misses by $0.10
INmune Bio | 10-Q: Q3 2024 Earnings Report
Express News | INmune Bio Q3 Operating Income USD -12.286 Million
Press Release: INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
INmune Bio 3Q Loss/Shr 60c >INMB
Here Are the Major Earnings After the Close Today
INmune Bio Q3 2024 Earnings Preview
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
Earnings Preview: INmune Bio to Report Financial Results Post-market on October 31
$INmune Bio(INMB.US)$ is scheduled to release its financial results post-market on October 31 ET. Earnings PreviewAnalysts estimate $INmune Bio(INMB.US)$ to post revenue of USD0 for 2024Q3, YoY-100%;
Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro Promotes Remyelination
Express News | INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024